Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so. |
|
Lucid Diagnostics Completes $70 Million Initial Public Offering |
|
Company’s esophageal cancer prevention tests developed jointly by Case Comprehensive Cancer Center members, medical school faculty at Case Western Reserve University and University Hospitals
Lucid Diagnostics Inc., a company that produces esophageal cancer tests based on Case Western Reserve University and University Hospitals research, has completed a $70 million initial public offering (IPO) on the Nasdaq Global Market; at the IPO price, the company’s estimated value would be $467 million.
Gastroesophageal reflux disease (GERD) affects about 20% of people in the United States. Many individuals with chronic GERD develop Barrett’s esophagus, which can lead to highly lethal esophageal cancer, the sixth-most common cause of cancer deaths worldwide.
Lucid Diagnostics Inc. (Nasdaq: LUCD), a subsidiary of New York-based PAVmed Inc. (Nasdaq: PAVM), licensed the EsoCheck and EsoGuard technology through Case Western Reserve’s Technology Transfer Office (TTO) in 2018. The U.S. Food and Drug Administration awarded both products Breakthrough Device designation, granted to novel medical devices with the potential to provide more effective treatment and diagnosis of life-threatening or irreversibly debilitating diseases and conditions. EsoCheck received a 2020 Edison Award as one of the year’s most significant innovations in the Medical Testing category.
EsoGuard is a next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. It has been shown to be highly accurate at detecting esophageal precancer and cancer. EsoGuard is commercially available in the United States and has received European CE mark certification. EsoCheck is a U.S. Food and Drug Administration-cleared and European CE Mark-certified noninvasive swallowable balloon capsule catheter device capable of performing targeted and protected sampling of surface esophageal cells in a less-than-five-minute office procedure.
|
|
The underlying technology for EsoCheck and EsoGuard was co-invented by Case Comprehensive Cancer Center members Sanford Markowitz, MD, PhD, the Ingalls Professor of Cancer Genetics and Medicine at the School of Medicine and an oncologist at University Hospitals (UH) Seidman Cancer Center; Amitabh Chak, MD, a professor of medicine at the School of Medicine, gastroenterologist at the University Hospitals Digestive Health Institute and the Brenda and Marshall B. Brown Master Clinician in Innovation and Discovery at UH Seidman Cancer Center; and Joseph Willis, MD, a professor of pathology at the School of Medicine and pathology vice-chair for translational research at UH. |
|
Great Lakes Breast Cancer Symposium: Last Chance to Register! |
|
It is almost time for the Great Lakes Breast Cancer Symposium, hosted virtually October 25-26 by the Case Comprehensive Cancer Center. This annual symposium highlights ongoing basic, translational, clinical and population studies addressing the biological mechanisms, management and prevention of breast cancer. Researchers from participating institutions will share their exciting work with the goal of developing cross-institutional collaborations. This event is an excellent opportunity to connect with other breast cancer experts. We have over 250 people attending so far, so please register ASAP and secure your spot!
Participants will be immersed in the latest developments in breast cancer research. Session topics include therapeutics-response resistance, survivorship and disparities, metastasis, cancer cell biology, and microenvironment and immunology. Plus, there will be a patient advocacy discussion.
Attendees will experience this virtual conference using Whova, our official web-based app, to view presentations, ask questions in real-time, and network with other attendees.
Are you already registered? Thank you! Please invite your colleagues to join us! Remember to log-in to Whova early to take advantage of the virtual platform to post jobs, ask questions and network with your fellow breast cancer researchers.
The Great Lakes Breast Cancer Symposium is made possible through the collaboration of the Case Comprehensive Cancer Center, Ohio State University Comprehensive Cancer Center (The James), the UPMC Hillman Cancer Center affiliated with the University of Pittsburgh Schools of the Health Sciences and the WVU Cancer Institute at West Virginia University.
|
|
No Cancer Center Seminar Series: TODAY, October 22 |
|
There will be no Cancer Center Seminar Series today or next week. We will return November 5 to hear from invited speaker Chaitra Badve, MD, of the Case Western Reserve University School of Medicine and University Hospitals. |
|
October 22, 2021- Homecoming weekend. No seminar
October 29, 2021 - External Advisory Committee meeting. No seminar
|
|
November 5, 2021
Physician, Radiology, Neuroradiology/Diagnostic Radiology, University Hospitals Cleveland Medical Center; Clinical Director, MRI, University Hospitals
Assistant Professor, Department of Radiology; Member, Cancer Imaging Program, Case Comprehensive Cancer Center, Case Western Reserve School of Medicine
Presented by the Cancer Imaging Program
*In-person seminar taking place in BRB 105
|
|
November 12, 2021
Professor, Epidemiology, Pathology and Laboratory Medicine
Director, Center for Environmental Health and Technology
Head, Environmental Health Section, Department of Epidemiology
Brown University
Presented by the Population and Cancer Prevention Program
*Seminar presented via Zoom only.
|
|
November 19, 2021
Assistant Professor, Medicine, Harvard Medical School
Director of Cellular Immunotherapy, Cancer Center
Massachusetts General Hospital
Presented by the Immune Oncology Program
|
|
AACR Launches Two Career Development Awards to Encourage Diversity in the Cancer Research Workforce
The American Association for Cancer Research (AACR) recently announced the creation of two career development awards (CDAs) to further diversity, equity, and inclusion in cancer research: one for basic, translational, or population sciences research; the other for clinical cancer research. The AACR is now accepting applications for the awards.
These new awards provide three years of support to early-career investigators from racial or ethnic groups that are underrepresented in cancer-related sciences. In addition to financial support, grantees will have the opportunity to interact and collaborate with other AACR-funded investigators as well as the greater AACR membership community. In coordination with the AACR’s Minorities in Cancer Research (MICR) constituency group, grantees will be provided opportunities to attend professional development sessions and to engage with colleagues and potential mentors.
These CDAs are part of the AACR’s broader commitment to diversifying the cancer research workforce and ensuring that underrepresented minority scientists are engaged, supported, and retained throughout their careers. To date, AbbVie, AstraZeneca, and Merck have donated to the program.
The AACR will accept applications for the two awards through November 30, 2021.
|
|
Mon, Oct 25
Great Lakes Breast Cancer Symposium
GMI Seminar Series
Case CCC Metabolism
DPB Seminar
4p Robbins E-501
|
|
Tues, Oct 26
Great Lakes Breast Cancer Symposium
Radiation Oncology Grand Rounds Lecture Series
8:15a Lerner Tower B-151
MetroHealth Research-in-Progress and Seminar Series
|
|
Wed, Oct 27
Case CCC Cancer Imaging
|
|
Thurs, Oct 28
Henry Z. Sable Distinguished Lecture
4p BRB 105
|
|
Fri, Oct 29
22nd Annual Brain Tumor Update and the 11th Annual Symposium on Brain Metastases and Spine Tumors
Oct 29-30 Zoom
Taussig Cancer Institute Grand Rounds
8a
Hematology and Oncology Research Grand Rounds
Cancer Center Seminar Series
No Seminar - External Advisory Committee meeting
|
|
|
Mon, Nov 1
CanSUR Applications open
|
|
Tues, Nov 2
Radiation Oncology Grand Rounds Lecture Series
8:15a Lerner Tower B-151
MetroHealth Research-in-Progress and Seminar Series
Case CCC Cancer Immunology
|
|
Fri, Nov 5
Taussig Cancer Institute Grand Rounds
8a
Cancer Center Seminar Series
BRB 105
|
|
 |
Great Lakes Breast Cancer Symposium
October 25-26, 2021 | Virtual
|
This annual symposium highlights ongoing basic, translational, clinical and population studies addressing the biological mechanisms, management and prevention of breast cancer. Researchers from participating institutions will share their exciting work with a goal to develop cross-institutional collaborations.
Program topics include: therapeutics-response resistance, survivorship and disparities, metastasis, cancer cell biology, and microenvironment and immunology. Plus, there will be a patient advocacy session.
|
Keynote Presentation: "Tackling Resistance in Triple-negative Breast Cancer"
Helen Piwnica-Worms, PhD, will deliver a keynote at the symposium. Dr. Piwnica-Worms is Professor, Department of Experimental Radiation Oncology, Division of Radiation Oncology and Senator AM Aiken Jr. Distinguished Chair at University of Texas MD Anderson Cancer Center.
Thanks to our Sponsors and Exhibitors
AstraZeneca, Lilly Oncology, Pfizer Oncology, Seagen, Daiichi Sankyo, Genentech, Novartis and Puma Biotechnology.
|
|
|
|
Artificial Intelligence in Oncology Symposium
November 8-9, 2021 | Virtual
|
You're invited to attend the 2021 Artificial Intelligence in Oncology Symposium: Precision Medicine and Cancer Disparities. This symposium will bring together clinicians, biomedical engineers, computer scientists, executives, thought leaders, and entrepreneurs with expertise in precision medicine, AI, machine learning, and oncology. These experts will discuss technical advances in AI, the challenges and advancements in deploying AI in the clinic, the need for the use of AI to address health disparities, the current regulatory and reimbursement landscape for AI in medicine, and the potential of AI to impact global health.
Discount registration for students and trainees!
|
Keynote Presentation: "AI Enabled Re-Thinking of Microscopy for All-Digital Cancer Pathology"
Rohit Bhargava, PhD
Director and Professor, Bioengineering, Founder Professor of Engineering; Director of the Cancer Center, University of Illinois at Urbana-Champaign
|
Thanks to our Sponsors and Exhibitors
Aiforia, dynam.AI and the University of Illinois Urbana-Champaign Department of Bioengineering.
|
|
|
|
6th Annual Cancer Disparities Symposium: The Intersection of Racism, Poverty and Biology in Cancer Prevention, Diagnosis and Treatment
March 3-4, 2022 | Virtual Event
Registration is open for the 6th Annual Cancer Disparities Symposium: "The Intersection of Racism, Poverty and Biology in Cancer Prevention, Diagnosis and Treatment," presented by the Case Comprehensive Cancer Center Office of Community Outreach and Engagement.
This multi-disciplinary event will appeal to researchers, clinicians, health professionals, community outreach groups, community-based organizations, patient advocates and trainees. Keynote presentations will be delivered by renowned disparities researchers and community leaders, and a poster session highlighting academic research and community programs will provide a showcase of the depth and breadth of work happening in this field. Plus, there will be a discussion of "Biased: Uncovering the Hidden Prejudice That Shapes What We See, Think, and Do," a book by Jennifer L. Eberhardt.
|
|
Keynote Speaker
Professor, Radiation Oncology
Vice Provost for Academic and Faculty Affairs
University of Michigan
|
|
Additional Upcoming Events |
|
|
NIH Virtual Seminar on Program Funding and Grants Administration
November 1-4, 2021 | Virtual
We are excited to share an opportunity to join the National Cancer Institute (NCI) at the 2021 NIH Virtual Seminar on Program Funding and Grants Administration from November 1–4, 2021! The theme for this year’s seminar is “Empowering the Research Workforce to Fuel Scientific Discovery.” There will be opportunities to learn about NIH and NCI funding opportunities, tools for applying, resources, and loads of networking with colleagues and federal staff.
Who should attend? We encourage you to share with your organization’s administrators, researchers, early-stage investigators, graduate students, or anyone new to working with the NIH grants process, as this seminar is designed specifically for them. Those who are more experienced are encouraged to attend the policy updates, check out the case study series, and visit NCI’s booth for resources.
|
|
|
|
|
AACR Annual Meeting 2022: Abstract Submission Reminder
April 8-13, 2022 | New Orleans, LA
Oral and poster presentations selected from proffered abstracts are a vital part of the AACR Annual Meeting program. Every proffered abstract that is accepted for publication in the Proceedings of the AACR is scheduled for presentation at the meeting, and all abstracts are considered for oral presentation in minisymposia.
Abstract submissions are due by Thursday, Nov. 18, 2021.
Update your calendar with these additional upcoming deadlines:
- November 18, 2021: Application Deadlines for Awards to Support Annual Meeting Attendance
- January 10, 2022: Clinical Trials Abstract Submission Deadline
|
|
|
|
22nd Annual Brain Tumor Update and the 11th Annual Symposium on Brain Metastases and Spine Tumors
October 29-30, 2021 | Livestream
|
This symposium is co-provided by Cleveland Clinic and Keck School of Medicine of the University of Southern California. This advanced multidisciplinary virtual meeting is led by expert faculty from Cleveland Clinic and USC, with additional internationally recognized guest faculty. This symposium is designed to improve competence to assess and treat patients with brain tumors and primary tumors of the spine, especially as it relates to comparing treatments for brain metastases and primary spine tumors, evaluating new technologies, treating vestibular schwannomas, and assessing and treating gliomas, with the overall goal of improving outcomes in these patient populations. |
|
|
|
Letters of Intent: TODAY, October 22, 2021
Full Applications: November 5, 2021
The Case Comprehensive Cancer Center, with funds from its American Cancer Society Institutional Research Grant, will provide seed money to foster cancer research by junior faculty who have no current national grant support of their own. Investigators in the CWRU School of Medicine, University Hospitals of Cleveland, and Cleveland Clinic Lerner College of Medicine as well as in other schools and colleges affiliated with Case Western Reserve University are eligible. Grants, not to exceed $40,000, will be awarded to investigators who intend to gather preliminary data to be used in seeking future and independently funded programs.
The American Cancer Society Institutional Research Grant at the Case Comprehensive Cancer Center was also recently awarded a Diversity Equity and Inclusion supplement. Persons from underrepresented racial or ethnic groups are particularly encouraged to apply.
|
|
St. Baldrick's Foundation Spring Grant Cycle
LOI Deadline: December 3, 2021, by 5PM ET
The St. Baldrick’s Foundation is a volunteer- and donor-powered charity committed to supporting the most promising research. We’re determined to find cures for childhood cancers and give survivors long and healthy lives.
Due to the impact of Covid-19 on fundraising, St. Baldrick’s will be only be offering grants in the following two funding categories in this grant cycle:
|
|
Star Beacon - Oct 21, 2021
There are a number of resources available to help women dealing with breast cancer. Dr. Alberto Montero, Director of the Breast Cancer Program at UH Seidman Cancer Center, said it is important for patients to have a strong support system.
|
|
Healthline - Oct 19, 2021
Triple-negative breast cancer (TNBC) disproportionately affects Black women who can experience a more severe course of the disease. Dr. Chirag Shah discusses the importance of getting regular mammogram screenings.
|
|
Weekly NIH Funding Opportunities and Notices |
|
Funding Opportunities
Notices
|
|
Use the button below to submit all your news, publications, events, announcements, lab openings and communications requests to the Case CCC Marketing and Communications team! We are here to help. |
|
|
|
|
|
|
